 |
|
|
| |
Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir
+ Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results
|
| |
| |
17th EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
Romina Quercia,1 Chloe Orkin,2 Ronald D'Amico,3 Joseph M. Mrus,3 Sterling Wu,4 Amy Cutrell,3 Ken Chow,5 Joseph W. Polli,3 David A. Margolis,3 Peter Williams,6 Annemiek de Ruiter,1
Kimberly Smith,3 William R. Spreen3
1ViiV Healthcare, Research Triangle Park, Brentford, UK; 2Queen Mary University, London, UK; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4GlaxoSmithKline, Collegeville, PA, USA; 5GlaxoSmithKline, Mississauga, Ontario, Canada; 6Janssen Research & Development, Beerse, Belgium
|
| |
|
|
|
|
|
